|
CA2711938C
(en)
|
2008-01-15 |
2019-11-12 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods for manipulating phagocytosis mediated by cd47
|
|
MX2015007446A
(es)
|
2012-12-12 |
2015-12-07 |
Vasculox Inc |
Anticuerpos terapeuticos para cd47.
|
|
US9221908B2
(en)
|
2012-12-12 |
2015-12-29 |
Vasculox, Inc. |
Therapeutic CD47 antibodies
|
|
EP4116331A1
(en)
|
2012-12-17 |
2023-01-11 |
PF Argentum IP Holdings LLC |
Treatment of cd47+ disease cells with sirp alpha-fc fusions
|
|
WO2016015095A1
(en)
*
|
2014-07-31 |
2016-02-04 |
The University Of Western Australia |
A method for the identification of immunotherapy-drug combinations using a network approach
|
|
CA2964173A1
(en)
*
|
2014-10-10 |
2016-04-14 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Methods to eliminate cancer stem cells by targeting cd47
|
|
JP6857603B2
(ja)
*
|
2014-11-18 |
2021-04-14 |
ヤンセン ファーマシューティカ エヌ．ベー． |
抗ｃｄ１４７抗体、方法及び使用
|
|
KR102313073B1
(ko)
|
2014-12-05 |
2021-10-18 |
리제너론 파마슈티칼스 인코포레이티드 |
인간화 분화 클러스터 47 유전자를 가진 비인간 동물
|
|
US20170151281A1
(en)
|
2015-02-19 |
2017-06-01 |
Batu Biologics, Inc. |
Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer
|
|
MX385673B
(es)
*
|
2015-03-04 |
2025-03-04 |
Yuhan Corp |
Productos terapeuticos de anticuerpos que se enlazan a cd47.
|
|
CN104804093A
(zh)
*
|
2015-05-27 |
2015-07-29 |
江苏春申堂药业有限公司 |
一种针对cd47的单域抗体
|
|
WO2017035480A1
(en)
|
2015-08-26 |
2017-03-02 |
The Board Of Trustees Of The Leland Stanford Junior University |
Enhanced depletion of targeted cells with cd47 blockade and an immune costimulatory agonist
|
|
WO2017044859A1
(en)
*
|
2015-09-10 |
2017-03-16 |
Affigen, Inc. |
Sequencing-directed selection of tumor theranostics
|
|
MX2018003374A
(es)
|
2015-09-18 |
2018-11-09 |
Arch Oncology Inc |
Anticuerpos terapeuticos cd47.
|
|
CN108290948B
(zh)
|
2015-09-21 |
2021-10-29 |
伊拉兹马斯大学医疗中心 |
抗-cd47抗体及使用方法
|
|
EP3708588A1
(en)
|
2015-11-27 |
2020-09-16 |
Cartherics Pty. Ltd. |
Genetically modified cells and uses thereof
|
|
KR102815803B1
(ko)
|
2015-12-02 |
2025-06-05 |
주식회사 에스티사이언스 |
당화된 btla(b- 및 t-림프구 약화인자)에 특이적인 항체
|
|
MX2018008558A
(es)
|
2016-01-11 |
2019-05-06 |
Forty Seven Inc |
Anticuerpos monoclonales anti-cd47 humanizados, de raton, o quimericos.
|
|
JP7026047B2
(ja)
*
|
2016-01-21 |
2022-02-25 |
ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー |
免疫調節剤を併用するがんの治療
|
|
JP2019511552A
(ja)
*
|
2016-04-15 |
2019-04-25 |
トリリウム セラピューティクス インコーポレイテッド |
Ｃｄ４７遮断療法におけるマクロファージの刺激
|
|
US12344669B2
(en)
|
2016-06-17 |
2025-07-01 |
Changchun Genescience Pharmaceutical Co., Ltd. |
Anti-CD47 monoclonal antibody and use thereof
|
|
CN106084052B
(zh)
*
|
2016-06-17 |
2019-12-27 |
长春金赛药业股份有限公司 |
抗cd47单克隆抗体及其应用
|
|
CN106117354B
(zh)
*
|
2016-06-24 |
2020-01-14 |
安徽未名细胞治疗有限公司 |
一种全人源抗CD47的全分子IgG抗体及其应用
|
|
US11618784B2
(en)
|
2016-07-19 |
2023-04-04 |
Teva Pharmaceuticals Australia Pty Ltd. |
Anti-CD47 combination therapy
|
|
CA2999058C
(en)
|
2016-10-20 |
2024-03-12 |
I-Mab |
Novel cd47 monoclonal antibodies and uses thereof
|
|
WO2018075960A1
(en)
|
2016-10-21 |
2018-04-26 |
Tioma Therapeutics, Inc. |
Therapeutic cd47 antibodies
|
|
EP3534964A4
(en)
|
2016-11-03 |
2020-07-15 |
Trillium Therapeutics Inc. |
IMPROVEMENT OF CD47 BLOCKING THERAPY BY PROTEASOME INHIBITORS
|
|
CN108779179B
(zh)
*
|
2016-11-28 |
2022-02-08 |
江苏恒瑞医药股份有限公司 |
Cd47抗体、其抗原结合片段及其医药用途
|
|
EP3345924A1
(en)
*
|
2017-01-10 |
2018-07-11 |
Universität Duisburg-Essen |
Use of cd47 antibodies
|
|
GB201700621D0
(en)
|
2017-01-13 |
2017-03-01 |
Guest Ryan Dominic |
Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue
|
|
WO2018137705A1
(en)
*
|
2017-01-26 |
2018-08-02 |
Zai Lab (Shanghai) Co., Ltd. |
Cd47 antigen binding unit and uses thereof
|
|
CN110612309A
(zh)
*
|
2017-03-27 |
2019-12-24 |
细胞基因公司 |
用于降低免疫原性的方法和组合物
|
|
WO2018176132A1
(en)
*
|
2017-03-28 |
2018-10-04 |
Trillium Therapeutics Inc. |
Cd47 blockade therapy
|
|
JP7097438B2
(ja)
|
2017-07-11 |
2022-07-07 |
アクティム・セラピューティクス・インコーポレイテッド |
遺伝子操作された免疫刺激性細菌菌株およびその使用
|
|
EP3661965A4
(en)
*
|
2017-08-02 |
2022-07-13 |
Phanes Therapeutics, Inc. |
ANTI-CD47 ANTIBODIES AND USES THEREOF
|
|
AU2018316742B2
(en)
*
|
2017-08-18 |
2025-04-10 |
Centessa Pharmaceuticals (Uk) Limited |
Binding agents
|
|
CN109422811A
(zh)
|
2017-08-29 |
2019-03-05 |
信达生物制药(苏州)有限公司 |
抗cd47抗体及其用途
|
|
RU2698048C2
(ru)
|
2017-10-03 |
2019-08-21 |
Закрытое Акционерное Общество "Биокад" |
МОНОКЛОНАЛЬНОЕ АНТИТЕЛО К IL-5Rα
|
|
EA039662B1
(ru)
|
2017-10-03 |
2022-02-24 |
Закрытое Акционерное Общество "Биокад" |
Антитела, специфичные к cd47 и pd-l1
|
|
AU2018351006B2
(en)
|
2017-10-18 |
2024-08-29 |
Forty Seven, LLC |
Anti-CD47 agent-based ovarian cancer therapy
|
|
WO2019086573A1
(en)
|
2017-11-01 |
2019-05-09 |
Hummingbird Bioscience Holdings Pte. Ltd. |
Cd47 antigen-binding molecules
|
|
WO2019090355A1
(en)
*
|
2017-11-06 |
2019-05-09 |
Children's National Medical Center |
Cells expressing antibodies and methods of treatment using the same
|
|
EP3706775A4
(en)
|
2017-11-06 |
2021-09-01 |
Trillium Therapeutics Inc. |
BLOCKING OF CD47 ASSOCIATED WITH RADIATION THERAPY
|
|
US11180552B2
(en)
|
2017-12-01 |
2021-11-23 |
Seagen Inc. |
CD47 antibodies and uses thereof for treating cancer
|
|
CN110144009B
(zh)
*
|
2018-02-14 |
2020-01-21 |
上海洛启生物医药技术有限公司 |
Cd47单域抗体及其用途
|
|
GB201804860D0
(en)
|
2018-03-27 |
2018-05-09 |
Ultrahuman Two Ltd |
CD47 Binding agents
|
|
CN110305212A
(zh)
|
2018-03-27 |
2019-10-08 |
信达生物制药(苏州)有限公司 |
抗cd47抗体及其用途
|
|
US20210155691A1
(en)
*
|
2018-04-16 |
2021-05-27 |
Adaerata, Limited Partnership |
Methods of preventing or treating non-hematopoietic slamf7 positive and slamf7 negative cancers
|
|
CN108484770B
(zh)
*
|
2018-05-16 |
2020-11-13 |
武汉云克隆科技股份有限公司 |
重组大鼠抗小鼠cd4单克隆抗体，制备方法和应用
|
|
CN110538321B
(zh)
*
|
2018-05-29 |
2023-03-10 |
江苏恒瑞医药股份有限公司 |
一种cd47抗体药物组合物及其用途
|
|
CN112566662A
(zh)
*
|
2018-06-15 |
2021-03-26 |
阿库鲁斯生物科学公司 |
针对cd47的阻断抗体及其使用方法
|
|
CN110615841B
(zh)
*
|
2018-06-20 |
2022-01-04 |
瑞阳(苏州)生物科技有限公司 |
抗人cd47单克隆抗体及其应用
|
|
WO2020014543A2
(en)
|
2018-07-11 |
2020-01-16 |
Actym Therapeutics, Inc. |
Engineered immunostimulatory bacterial strains and uses thereof
|
|
WO2020036977A1
(en)
*
|
2018-08-13 |
2020-02-20 |
Arch Oncology, Inc. |
Therapeutic cd47 antibodies
|
|
WO2020047161A2
(en)
|
2018-08-28 |
2020-03-05 |
Actym Therapeutics, Inc. |
Engineered immunostimulatory bacterial strains and uses thereof
|
|
KR102587442B1
(ko)
|
2018-08-31 |
2023-10-11 |
난징 산홈 팔마세우티칼 컴퍼니 리미티드 |
항-cd47 항체 또는 그 적용
|
|
US12331320B2
(en)
|
2018-10-10 |
2025-06-17 |
The Research Foundation For The State University Of New York |
Genome edited cancer cell vaccines
|
|
CA3118326A1
(en)
*
|
2018-10-29 |
2020-05-07 |
Umc Utrecht Holding B.V. |
Iga mediated killing of aberrant cells by cd47- sirpalpha checkpoint inhibition of neutrophils
|
|
EP3876977A1
(en)
|
2018-11-06 |
2021-09-15 |
The Regents Of The University Of California |
Chimeric antigen receptors for phagocytosis
|
|
CN113166257B
(zh)
*
|
2018-12-03 |
2023-05-30 |
上海开拓者生物医药有限公司 |
Cd47抗体及其制备方法和应用
|
|
EP3936526A4
(en)
|
2019-03-06 |
2023-03-08 |
Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
BIFUNCTIONAL FUSION PROTEIN AND PHARMACEUTICAL USE
|
|
US11013764B2
(en)
|
2019-04-30 |
2021-05-25 |
Myeloid Therapeutics, Inc. |
Engineered phagocytic receptor compositions and methods of use thereof
|
|
JP7561775B2
(ja)
|
2019-06-07 |
2024-10-04 |
エーエルエックス オンコロジー インコーポレイテッド |
血清学的アッセイにおいてｃｄ４７に結合する薬物の干渉を低減するための方法及び試薬
|
|
WO2020253785A1
(en)
*
|
2019-06-19 |
2020-12-24 |
Lepu Biopharma Co., Ltd. |
Anti-cd47 antibodies and uses thereof
|
|
KR20220024211A
(ko)
|
2019-06-19 |
2022-03-03 |
레푸 바이오파마 컴퍼니 리미티드 |
항-cd47 항체 및 그것의 사용
|
|
KR20220047277A
(ko)
|
2019-07-16 |
2022-04-15 |
길리애드 사이언시즈, 인코포레이티드 |
Hiv 백신, 및 이의 제조 및 사용 방법
|
|
WO2021018114A1
(zh)
*
|
2019-07-30 |
2021-02-04 |
中山康方生物医药有限公司 |
抗人p40蛋白域抗体及其用途
|
|
AU2020342192A1
(en)
*
|
2019-09-03 |
2022-04-21 |
Akeso Biopharma, Inc |
Anti-CD47 monoclonal antibody and use thereof
|
|
WO2021046243A2
(en)
|
2019-09-03 |
2021-03-11 |
Myeloid Therapeutics, Inc. |
Methods and compositions for genomic integration
|
|
US11795223B2
(en)
|
2019-10-18 |
2023-10-24 |
Forty Seven, Inc. |
Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia
|
|
CN114599681B
(zh)
*
|
2019-10-25 |
2024-01-09 |
上海药明生物技术有限公司 |
新型抗cd47抗体及其用途
|
|
NZ786589A
(en)
|
2019-10-31 |
2025-03-28 |
Forty Seven Llc |
Anti-cd47 and anti-cd20 based treatment of blood cancer
|
|
EP4061420A1
(en)
*
|
2019-11-20 |
2022-09-28 |
Abvision, Inc. |
Monoclonal antibodies that target human cd47 protein
|
|
US10980836B1
(en)
|
2019-12-11 |
2021-04-20 |
Myeloid Therapeutics, Inc. |
Therapeutic cell compositions and methods of manufacturing and use thereof
|
|
GB201918230D0
(en)
|
2019-12-11 |
2020-01-22 |
Prec Therapeutics Ltd |
Antibodies and their uses
|
|
KR20220119439A
(ko)
|
2019-12-20 |
2022-08-29 |
인스틸 바이오 유케이 리미티드 |
종양 침윤 림프구를 분리하기 위한 장치 및 방법 및 그것의 용도
|
|
MX2022007930A
(es)
|
2019-12-24 |
2022-08-08 |
Carna Biosciences Inc |
Compuestos moduladores de diacilglicerol quinasa.
|
|
TWI832035B
(zh)
|
2020-02-14 |
2024-02-11 |
美商基利科學股份有限公司 |
結合ccr8之抗體及融合蛋白及其用途
|
|
WO2021190441A1
(zh)
*
|
2020-03-23 |
2021-09-30 |
倍而达药业（苏州）有限公司 |
Cd47/人源化cd47抗体或其抗原结合片段、免疫活性片段及应用
|
|
JP2023519346A
(ja)
|
2020-03-27 |
2023-05-10 |
メンドゥス・ベスローテン・フェンノートシャップ |
養子細胞療法の有効性を増強するための白血病由来の改変細胞のエクスビボ（ｅｘ ｖｉｖｏ）使用
|
|
TW202144407A
(zh)
*
|
2020-04-02 |
2021-12-01 |
大陸商正大天晴藥業集團股份有限公司 |
結合cd47的抗原結合多肽及用途
|
|
CN111635459B
(zh)
*
|
2020-06-27 |
2021-01-15 |
广东赛尔生物科技有限公司 |
抗cd47抗体及其在治疗癌症中的应用
|
|
CN116133679A
(zh)
|
2020-06-30 |
2023-05-16 |
门德斯有限公司 |
白血病衍生细胞在卵巢癌疫苗中的用途
|
|
JP2023550544A
(ja)
|
2020-11-03 |
2023-12-01 |
アールディスカバリー エルエルシー |
がんおよびファゴサイトーシス不全に関連する疾患の処置のための療法
|
|
CA3197423A1
(en)
|
2020-11-04 |
2022-05-12 |
Daniel Getts |
Engineered chimeric fusion protein compositions and methods of use thereof
|
|
US20230399405A1
(en)
*
|
2020-11-04 |
2023-12-14 |
The Trustees Of Dartmouth College |
Vista agonist for treatment/prevention of ischemic and/or reperfusion injury
|
|
JP2023552375A
(ja)
|
2020-12-06 |
2023-12-15 |
エーエルエックス オンコロジー インコーポレイテッド |
血清学的アッセイにおいてｃｄ４７に結合する薬物の干渉を低減するための多量体
|
|
EP4262828A1
(en)
|
2020-12-18 |
2023-10-25 |
Instil Bio (Uk) Limited |
Tumor infiltrating lymphocytes and anti-cd47 therapeutics
|
|
WO2022177392A1
(ko)
*
|
2021-02-19 |
2022-08-25 |
(주)샤페론 |
Cd47에 대한 단일 도메인 항체 및 이의 용도
|
|
KR20230157388A
(ko)
|
2021-03-12 |
2023-11-16 |
멘두스 비.브이. |
백신접종의 방법 및 cd47 차단의 용도
|
|
CN112979764B
(zh)
*
|
2021-03-26 |
2022-08-02 |
复旦大学附属中山医院 |
特异结合人cd47分子的多肽及其用途
|
|
TW202302145A
(zh)
|
2021-04-14 |
2023-01-16 |
美商基利科學股份有限公司 |
ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症
|
|
WO2022241029A1
(en)
|
2021-05-11 |
2022-11-17 |
Myeloid Therapeutics, Inc. |
Methods and compositions for genomic integration
|
|
CA3222277A1
(en)
|
2021-06-23 |
2022-12-29 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
|
EP4359389A1
(en)
|
2021-06-23 |
2024-05-01 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
|
AU2022298639C1
(en)
|
2021-06-23 |
2025-07-17 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
|
JP7686091B2
(ja)
|
2021-06-23 |
2025-05-30 |
ギリアード サイエンシーズ， インコーポレイテッド |
ジアシルグリセロールキナーゼ調節化合物
|
|
CA3234909A1
(en)
|
2021-10-28 |
2023-05-04 |
Gilead Sciences, Inc. |
Pyridizin-3(2h)-one derivatives
|
|
JP2024541979A
(ja)
|
2021-10-29 |
2024-11-13 |
ギリアード サイエンシーズ， インコーポレイテッド |
Ｃｄ７３化合物
|
|
KR20240125012A
(ko)
|
2021-12-22 |
2024-08-19 |
길리애드 사이언시즈, 인코포레이티드 |
이카로스 아연 핑거 패밀리 분해제 및 이의 용도
|
|
CN118488946A
(zh)
|
2021-12-22 |
2024-08-13 |
吉利德科学公司 |
Ikaros锌指家族降解剂及其用途
|
|
TW202340168A
(zh)
|
2022-01-28 |
2023-10-16 |
美商基利科學股份有限公司 |
Ｐａｒｐ７抑制劑
|
|
WO2023159220A1
(en)
*
|
2022-02-18 |
2023-08-24 |
Kenjockety Biotechnology, Inc. |
Anti-cd47 antibodies
|
|
DK4245756T3
(da)
|
2022-03-17 |
2024-10-21 |
Gilead Sciences Inc |
Ikaros zinkfinger-familiens nedbrydere og anvendelse heraf
|
|
US20230355796A1
(en)
|
2022-03-24 |
2023-11-09 |
Gilead Sciences, Inc. |
Combination therapy for treating trop-2 expressing cancers
|
|
TWI876305B
(zh)
|
2022-04-05 |
2025-03-11 |
美商基利科學股份有限公司 |
用於治療結腸直腸癌之組合療法
|
|
IL316058A
(en)
|
2022-04-21 |
2024-11-01 |
Gilead Sciences Inc |
Compounds modulate KRAS G12D
|
|
CR20240570A
(es)
|
2022-07-01 |
2025-03-03 |
Gilead Sciences Inc |
Compuestos de cd73
|
|
AU2023307100A1
(en)
|
2022-07-12 |
2025-01-02 |
Gilead Sciences, Inc. |
Hiv immunogenic polypeptides and vaccines and uses thereof
|
|
WO2024064668A1
(en)
|
2022-09-21 |
2024-03-28 |
Gilead Sciences, Inc. |
FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY
|
|
KR20250122479A
(ko)
|
2022-12-22 |
2025-08-13 |
길리애드 사이언시즈, 인코포레이티드 |
Prmt5 억제제 및 이의 용도
|
|
US20240383922A1
(en)
|
2023-04-11 |
2024-11-21 |
Gilead Sciences, Inc. |
KRAS Modulating Compounds
|
|
AU2024259556A1
(en)
|
2023-04-21 |
2025-10-23 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
WO2025006720A1
(en)
|
2023-06-30 |
2025-01-02 |
Gilead Sciences, Inc. |
Kras modulating compounds
|
|
WO2025024663A1
(en)
|
2023-07-26 |
2025-01-30 |
Gilead Sciences, Inc. |
Parp7 inhibitors
|
|
US20250100998A1
(en)
|
2023-07-26 |
2025-03-27 |
Gilead Sciences, Inc. |
Parp7 inhibitors
|
|
WO2025054347A1
(en)
|
2023-09-08 |
2025-03-13 |
Gilead Sciences, Inc. |
Kras g12d modulating compounds
|
|
US20250109147A1
(en)
|
2023-09-08 |
2025-04-03 |
Gilead Sciences, Inc. |
Kras g12d modulating compounds
|
|
US20250154172A1
(en)
|
2023-11-03 |
2025-05-15 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
US20250230168A1
(en)
|
2023-12-22 |
2025-07-17 |
Gilead Sciences, Inc. |
Azaspiro wrn inhibitors
|
|
CN120648654A
(zh)
*
|
2024-03-13 |
2025-09-16 |
深圳太力生物技术有限责任公司 |
重组细胞的制备方法、重组细胞及其应用
|
|
WO2025245003A1
(en)
|
2024-05-21 |
2025-11-27 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|